Limits...
Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats.

Yan J, Yang X, Han D, Feng J - Mol Med Rep (2016)

Bottom Line: Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown.Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents.The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.

ABSTRACT
Multiple sclerosis (MS) is an inflammatory autoimmune neurodegenerative disease, which features focal demyelination and inflammatory cell infiltration of the brain and the spinal cord. Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown. The current study was designed to investigate the potential therapeutic function of TSIIA on MS in the experimental autoimmune encephalomyelitis (EAE) rat model. In comparison to the vehicle control group, the TSIIA‑treated groups showed notably improved clinical symptoms and pathological changes, including central nervous system inflammatory cell infiltration and demyelination. Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents. Furthermore, TSIIA was also shown to downregulate interleukin (IL)‑17 and IL‑23 levels in the brain and serum of EAE rats. The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

No MeSH data available.


Related in: MedlinePlus

Measurement of serum production of (A) IL-17 and (B) IL-23 via enzyme-linked immunosorbent assay. ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01 or or n (not significant) compared with the TSIIA-H group. IL, interleukin; TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940100&req=5

f6-mmr-14-02-1601: Measurement of serum production of (A) IL-17 and (B) IL-23 via enzyme-linked immunosorbent assay. ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01 or or n (not significant) compared with the TSIIA-H group. IL, interleukin; TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.

Mentions: The serum contents of IL-17 and IL-23 are usually upregulated and closely associated with the development of EAE. The highest concentrations of serum IL-17 and IL-23 among all groups were found in vehicle-treated rats, which decreased significantly in the two TSIIA-treated groups (P<0.01). The serum level of IL-17 in the TSIIA-H group was lower than that in the TSIIA-L group (P<0.01). However, no significant difference was identified in the serum concentrations of IL-23 between the two TSIIA-treated groups (Fig. 6).


Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats.

Yan J, Yang X, Han D, Feng J - Mol Med Rep (2016)

Measurement of serum production of (A) IL-17 and (B) IL-23 via enzyme-linked immunosorbent assay. ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01 or or n (not significant) compared with the TSIIA-H group. IL, interleukin; TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940100&req=5

f6-mmr-14-02-1601: Measurement of serum production of (A) IL-17 and (B) IL-23 via enzyme-linked immunosorbent assay. ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01 or or n (not significant) compared with the TSIIA-H group. IL, interleukin; TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
Mentions: The serum contents of IL-17 and IL-23 are usually upregulated and closely associated with the development of EAE. The highest concentrations of serum IL-17 and IL-23 among all groups were found in vehicle-treated rats, which decreased significantly in the two TSIIA-treated groups (P<0.01). The serum level of IL-17 in the TSIIA-H group was lower than that in the TSIIA-L group (P<0.01). However, no significant difference was identified in the serum concentrations of IL-23 between the two TSIIA-treated groups (Fig. 6).

Bottom Line: Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown.Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents.The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.

ABSTRACT
Multiple sclerosis (MS) is an inflammatory autoimmune neurodegenerative disease, which features focal demyelination and inflammatory cell infiltration of the brain and the spinal cord. Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown. The current study was designed to investigate the potential therapeutic function of TSIIA on MS in the experimental autoimmune encephalomyelitis (EAE) rat model. In comparison to the vehicle control group, the TSIIA‑treated groups showed notably improved clinical symptoms and pathological changes, including central nervous system inflammatory cell infiltration and demyelination. Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents. Furthermore, TSIIA was also shown to downregulate interleukin (IL)‑17 and IL‑23 levels in the brain and serum of EAE rats. The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

No MeSH data available.


Related in: MedlinePlus